CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-18 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,400 | 175,980 | ||
| 2025-07-17 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +2,700 | $9.45 | $26K | 189,864 |
| 2025-07-17 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,000 | $350.10 | $700K | 187,864 |
| 2025-07-17 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −700 | $351.57 | $246K | 187,164 |
| 2025-07-17 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,700 | 177,380 | ||
| 2025-07-17 | Taub Rebecca Director | Option exercise 10b5-1 | +2,657 | $9.45 | $25K | 463,701 |
| 2025-07-17 | Taub Rebecca Director | Sale 10b5-1 | −2,057 | $350.09 | $720K | 461,644 |
| 2025-07-17 | Taub Rebecca Director | Sale 10b5-1 | −600 | $351.50 | $211K | 461,044 |
| 2025-07-17 | Taub Rebecca Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,657 | 47,463 | ||
| 2025-07-16 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +26,176 | $9.45 | $247K | 213,340 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,541 | $350.17 | $1.9M | 207,799 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,371 | $351.38 | $833K | 205,428 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,110 | $352.67 | $744K | 203,318 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,319 | $353.82 | $821K | 200,999 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −6,851 | $354.65 | $2.4M | 194,148 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,784 | $355.61 | $2.1M | 188,364 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,200 | $356.62 | $428K | 187,164 |
| 2025-07-16 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −26,176 | 180,080 | ||
| 2025-07-16 | Taub Rebecca Director | Option exercise 10b5-1 | +26,444 | $9.45 | $250K | 487,488 |
| 2025-07-16 | Taub Rebecca Director | Sale 10b5-1 | −6,000 | $350.19 | $2.1M | 481,488 |
Page 21 of 82 · 1,629 trades